Request Demo
Last update 04 Jul 2026
4-[18F]fluoro-meta-hydroxyphenethylguanidine
Last update 04 Jul 2026
Overview
Basic Info
Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms [18F]4F-MHPG |
Target |
Action modulators, enhancers |
Mechanism SLC6A2 modulators(Norepinephrine transporter modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with 4-[18F]fluoro-meta-hydroxyphenethylguanidineNCT02669563
An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients
NCT02385877
Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET
100 Clinical Results associated with 4-[18F]fluoro-meta-hydroxyphenethylguanidine
Login to view more data
100 Translational Medicine associated with 4-[18F]fluoro-meta-hydroxyphenethylguanidine
Login to view more data
100 Patents (Medical) associated with 4-[18F]fluoro-meta-hydroxyphenethylguanidine
Login to view more data
1
Literatures (Medical) associated with 4-[18F]fluoro-meta-hydroxyphenethylguanidine19 Dec 2025JOURNAL OF ORGANIC CHEMISTRY
Automated Synthesis of NET-Targeted PET Tracers [
18
F]4F-mHPG and [
18
F]3F-pHPG through Photocatalyzed
18
F-Deoxyfluorination
Article
Author: Wu, Xiaoai ; Xie, Yang ; Wang, Yueqi ; Yin, Honghai ; Hu, Mingxing ; Chen, Wei ; Pan, Lili ; Cao, Yarong
The NET-targeted radiotracers [18F]4F-mHPG and [18F]3F-pHPG have demonstrated promising clinical applications; however, the preparation of these tracers remains challenging. Herein, we report an improved synthesis protocol that enables the efficient automated production of two PET tracers via photocatalyzed 18F-deoxyfluorination. [18F]4F-mHPG and [18F]3F-pHPG were prepared in excellent n.d.c. RCYs of 31.3 ± 0.4% and 22.4 ± 1% in only 1 h from readily available precursors, and further validated on the PC12 tumor model for head-to-head comparison.
100 Deals associated with 4-[18F]fluoro-meta-hydroxyphenethylguanidine
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiomyopathies | Phase 1 | United States | 01 Dec 2015 | |
| Heart Failure | Phase 1 | United States | 01 Dec 2015 | |
| Autonomic Nervous System Diseases | Phase 1 | United States | 01 Mar 2015 | |
| Neoplasms | Preclinical | China | 05 Dec 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free